Search results for "Rectal Cancer"

showing 10 items of 978 documents

PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients

2012

PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy. Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry. PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients wit…

OncologyMaleOrganoplatinum CompoundsOxaloacetatesPhysiologyColorectal cancerSettore MED/06 - Oncologia MedicavirusesClinical BiochemistryCellLeucovorinPromyelocytic Leukemia Proteinmedicine.disease_causeDeoxycytidineAntineoplastic Combined Chemotherapy Protocolsbiologyvirus diseasesNuclear ProteinsMiddle AgedOxaliplatinSurvival Ratemedicine.anatomical_structureImmunohistochemistryoxaliplatin/fluoropyrimidineFemaleFluorouracilColorectal Neoplasmsmedicine.drugAdultmedicine.medical_specialtyAntimetabolites AntineoplasticPML; oxaliplatin/fluoropyrimidine; colorectal cancerAntineoplastic Agentscolorectal cancerPromyelocytic leukemia proteinPredictive Value of TestsInternal medicinemedicineHumansCapecitabineAgedRetrospective StudiesPMLbusiness.industryTumor Suppressor ProteinsRetrospective cohort studyCell Biologymedicine.diseaseOxaliplatinApoptosisDrug Resistance Neoplasmbiology.proteinCarcinogenesisbusinessTranscription Factors
researchProduct

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study

2015

OBJECTIVE: We aimed to better clarify the role of germline variants of the FCG2 receptor, FCGR2A-H131R and FCGR3A-V158F, on the therapeutic efficacy of cetuximab in metastatic colorectal cancer (mCRC). A large cohort with sufficient statistical power was assembled.DESIGN: To show a HR advantage of 0.6 in progression-free survival (PFS) for FCGR2A-HH versus the rest and FCGR3A-VV versus the rest, with an 80% power, 80 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) wild-type (KRAS-WT) and 52 KRAS-WT patients are required, respectively. This leads to a total sample size of 952 and 619 patients, respectively. Samples were collected from 1123 mCRC patients from 15 European centres treated wit…

OncologyMaleReceptors IgG/geneticsGenotyping TechniquesColorectal cancermedicine.medical_treatmentCetuximabmedicine.disease_causeGenetic PolymorphismsErbB Receptors/antagonists & inhibitorsNeoplasm MetastasisAntibody Targeted TherapyImmune ResponseAged 80 and overbiologyCetuximabGastroenterologyColorectal Neoplasms/drug therapyMiddle AgedErbB ReceptorsSurvival RateAntibodies Monoclonal Humanized/therapeutic useFemaleKRASAntibodyColorectal Neoplasmsmedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsAntibodies Monoclonal HumanizedDisease-Free SurvivalYoung AdultRefractoryInternal medicinemedicineHumansneoplasmsGerm-Line MutationAgedColorectal CancerChemotherapyPolymorphism Geneticbusiness.industryReceptors IgGAntineoplastic Agents/therapeutic usemedicine.diseasedigestive system diseasesOxaliplatinIrinotecanImmunologybiology.proteinbusinessGenotyping Techniques/standards
researchProduct

Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer

2010

International audience; Hepatic arterial infusion (HAI) of chemotherapy can be performed in cases of liver-confined metastatic disease, resulting in increased local drug concentrations. Here we report the case of a 61-year-old man who presented with an isolated large unresectable liver metastasis of colon cancer after failure of surgery and multiple administration of systemic chemotherapy. The patient was treated with a combination of gemcitabine and oxaliplatin using HAI. The tolerance was excellent and a radiological complete response was obtained after 8 cycles of HAI. The rationale for the use of gemcitabine and oxaliplatin as well as that for the combination of the 2 drugs is discussed…

OncologyMale[SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/SurgeryOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentCase ReportDeoxycytidineMetastasischemistry.chemical_compound0302 clinical medicineHepatic ArteryAntineoplastic Combined Chemotherapy Protocols[ SDV.MHEP.CHI ] Life Sciences [q-bio]/Human health and pathology/Surgery0303 health sciencesLiver NeoplasmsGastroenterologyvirus diseasesGeneral MedicineMiddle AgedMagnetic Resonance Imaging3. Good healthOxaliplatinTreatment Outcome030220 oncology & carcinogenesisColonic NeoplasmsCatheter AblationAdenocarcinomaDeoxycytidinemedicine.drugmedicine.medical_specialtyanimal structures[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryAdenocarcinoma03 medical and health sciencesHepatic arterial infusionInternal medicinemedicineHumansInfusions Intra-Arterial030304 developmental biologyChemotherapybusiness.industrymedicine.diseaseGemcitabineGemcitabineOxaliplatinchemistrybusinessTomography X-Ray Computed
researchProduct

Role of Densitometric Criteria in Evaluation of Effectiveness of Antiangiogenic Therapies in Metastatic Colorectal Cancer: An Italian Clinical Experi…

2017

Background/Aim: To evaluate the role of densitometric criterion using the Choi Criteria in the assessment of the response to antiangiogenic treatments of metastatic colorectal cancer (mCRC) compared to the RECIST criteria. Patients and Methods: Fifty-four patients (mean age=50.6 years ) affected by advanced colorectal cancer and with hepatic and possibly peritoneal and pulmonary metastases, that can be treated with bevacizumab, were prospectively evaluated by computerized tomography (CT) scan. Metastases were also evaluated by CT in onedimensional form according to RECIST. Results: Results show that in 58% of analyzed cases, stable disease according to RECIST coincided with stable disease a…

OncologyMalemedicine.medical_specialtyCancer ResearchBevacizumabDensitometric criteriaColorectal cancerAntiangiogenic therapyAngiogenesis InhibitorsColorectal NeoplasmAdvanced colorectal cancerStable DiseaseChoi CriteriaInternal medicinePartial responseMultidetector Computed TomographymedicineHumansDemographybusiness.industryDisease progressionLiver NeoplasmsMean ageGeneral MedicineMiddle Agedmedicine.diseaseTreatment OutcomeRECISTOncologyItalyLiver NeoplasmCHOIFemaleMetastatic colorectal cancer (mCRC)businessColorectal Neoplasmsmedicine.drugAngiogenesis InhibitorHumanDensitometryAnticancer research
researchProduct

Exploring better strategies for EGFR antibodies in colon cancer.

2014

Summary Background Advanced colorectal cancer is treated with a combination of cytotoxic drugs and targeted treatments. However, how best to minimise the time spent taking cytotoxic drugs and whether molecular selection can refine this further is unknown. The primary aim of this study was to establish how cetuximab might be safely and effectively added to intermittent chemotherapy. Methods COIN-B was an open-label, multicentre, randomised, exploratory phase 2 trial done at 30 hospitals in the UK and one in Cyprus. We enrolled patients with advanced colorectal cancer who had received no previous chemotherapy for metastases. Randomisation was done centrally (by telephone) by the Medical Resea…

OncologyMalemedicine.medical_specialtyColorectal cancerMEDLINECetuximabAntibodies Monoclonal HumanizedInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansneoplasmsbiologyCetuximabbusiness.industryArticlesmedicine.diseasedigestive system diseasesOncologyMonoclonalbiology.proteinFemaleAntibodybusinessColorectal Neoplasmsmedicine.drugThe Lancet. Oncology
researchProduct

Vitamin D in cancer chemoprevention

2015

Context: There is increasing evidence that Vitamin D (Vit D) and its metabolites, besides their well-known calcium-related functions, may also exert antiproliferative, pro-differentiating, and immune modulatory effects on tumor cells in vitro and may also delay tumor growth in vivo. Objective: The aim of this review is to provide fresh insight into the most recent advances on the role of Vit D and its analogues as chemopreventive drugs in cancer therapy. Methods: A systematic review of experimental and clinical studies on Vit D and cancer was undertaken by using the major electronic health database including ISI Web of Science, Medline, PubMed, Scopus and Google Scholar. Results and conclus…

OncologyMalemedicine.medical_specialtyColorectal cancerPharmaceutical ScienceAntineoplastic AgentsBreast NeoplasmsPharmacologyChemopreventionMalignant transformationProstate cancerImmune systemBreast cancerInternal medicineNeoplasmsDrug DiscoverymedicineVitamin D and neurologyAnimalsHumansImmunologic FactorsVitamin DPharmacologyClinical Trials as TopicCancer preventionbusiness.industryCancerProstatic NeoplasmsGeneral Medicinemedicine.diseaseCancer cancer prevention calcitriol vitamin D vitamin D analoguesGrowth InhibitorsComplementary and alternative medicineSettore BIO/14 - FarmacologiaMolecular MedicineFemalebusinessColorectal Neoplasms
researchProduct

Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study.

2014

Epidemiological data on synchronous and metachronous metastatic colon cancer are scarce. We assessed epidemiological characteristics and survival in synchronous and metachronous metastatic colon cancer in a French population.Our study included 932 cases of metastatic colon cancer diagnosed in 1999-2010 and registered in a population-based cancer registry; 758 were synchronous colon metastases and 174 metachronous metastases from resected primary colon cancers diagnosed in 1999-2005. Univariate relative survival was calculated and a multivariate model with proportional hazard applied to net survival by interval was used.Mean age at diagnosis was 71.1 years for patients with metachronous meta…

OncologyMalemedicine.medical_specialtyColorectal cancermedicine.medical_treatmentPopulationNeoplasms Multiple PrimaryMetachronous metastasisRisk FactorsInternal medicineEpidemiologyMedicineHumanseducationAgedRetrospective StudiesChemotherapyeducation.field_of_studyHepatologyRelative survivalbusiness.industryGastroenterologyNeoplasms Second PrimaryOdds ratiomedicine.diseasePrognosisCancer registrySurvival RatePopulation SurveillanceColonic NeoplasmsFemaleFranceMorbiditybusinessFollow-Up StudiesDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatell…

2006

Background: K-ras mutations are a key step in colorectal cancer progression. Such mutations have been widely studied in case series from Western countries but there are few data on the rate and spectrum of mutations in tumors from countries where the epidemiological features of the disease are different. Patients and methods: Tumor samples from 182 Iranian colorectal cancer patients (170 sporadic cases and 12 HNPCC cases) were screened for K-ras mutations at codons 12, 13 and 61 by sequencing analysis. The cases were also characterized for microsatellite instability at mononucleotide repeats by PCR and fragment analysis, and classified according to microsatellite instability status. The fre…

OncologyMalemedicine.medical_specialtyK-ras mutationsColorectal cancerHNPCCDiseaseK-ras mutationIranmedicine.disease_causecolorectal carcinomaInternal medicineEpidemiologymedicineHumansCodoncolorectal carcinoma; HNPCC; gene-environment interaction; K-ras mutations; MSI; Iran; ItalyMSIGeneticsMutationbusiness.industryMicrosatellite instabilityHematologymedicine.diseasegene-environment interactionGenes rasOncologyItalyRAS MutationMutationFemaleMicrosatellite InstabilitybusinessColorectal Neoplasms
researchProduct

Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study.

2015

Background Cancer stem cells represent a population of immature tumor cells found in most solid tumors. Their peculiar features make them ideal models for studying drug resistance and sensitivity. In this study, we investigated whether cancer stem cells isolation and in vitro sensitivity assay are feasible in a clinical setting. Methods Cancer stem cells were isolated from effusions or fresh cancer tissue of 23 patients who progressed after standard therapy failure. Specific culture conditions selected for immature tumor cells that express markers of stemness. These cells were exposed in vitro to chemotherapeutic and targeted agents. Results Cancer stem cells were extracted from liver metas…

OncologyMalemedicine.medical_specialtyLung NeoplasmsTime FactorsColorectal cancerTarget therapy drug sensitivity cancer stem cellsPopulationlcsh:MedicineAntineoplastic AgentsDrug resistanceCell SeparationCancer stem cellInternal medicinemedicineHumansIn patienteducationlcsh:ScienceAgedAged 80 and overSettore MED/04 - Patologia Generaleeducation.field_of_studyMultidisciplinaryLungbusiness.industrylcsh:RLiver NeoplasmsMiddle Agedmedicine.diseaseIn vitroClinical trialPleural EffusionDrug Combinationsmedicine.anatomical_structureLymphatic MetastasisNeoplastic Stem CellsFeasibility Studieslcsh:QFemaleDrug Screening Assays AntitumorbusinessColorectal NeoplasmsResearch Article
researchProduct

Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer

2019

BACKGROUND: TNM stage has been identified as an independent variable for local recurrence and survival after colon cancer resection. It is still unclear whether peritoneal invasion (pT4a) is a risk factor for adverse oncologic outcome or whether these patients have better results compared with contiguous organs infiltration (pT4b), independent from nodal status (pN). OBJECTIVE: The purpose of this study was to analyze whether peritoneal invasion is an independent risk factor for worse oncologic outcome after curative colon cancer resection. DESIGN: This was a retrospective analysis with multivariate regression of a prospective database, according to Strengthening the Reporting of Observatio…

OncologyMalemedicine.medical_specialtySurvivalColorectal cancermedicine.medical_treatmentLocally advancedT stageLocally advanced colon cancer03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineColon cancer resectionHumansNeoplasm InvasivenessRisk factorStage (cooking)Survival rateColectomyPeritoneal NeoplasmsColectomyAgedNeoplasm StagingRetrospective StudiesCarcinomatosisTumor-node-metastasisbusiness.industryGastroenterologyRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseasePrognosisColon cancerSurvival RateTreatment Outcome030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologyFemaleNeoplasm Recurrence Localbusiness
researchProduct